Fig. 1
From: Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
Synthesis process of (Lipo + M)@E NPs and the inhibiting mechanism of phenotypic transition of VSMCs by reducing PCSK9. First, the nanoliposomes were used to carry Evol with high drug-loading efficiency. PEG was used to modify the nanoliposomes. Møm was used to camouflage Lipo@E NPs to form (Lipo+M)@E NPs. After intravenous administration, (Lipo + M)@E NPs inhibited the expression of PCSK9, leading to the upregulation of the levels of α-SMA and Vimentin, while inhibiting the expression of OPN, which finally result in the inhibition of the phenotypic transition, excessive proliferation, and migration of VSMCs, thus effectively treating atherosclerosis.